Alpha interferon combination zidovudine treatment presymptomatic feline leukemia virus-induced immunodeficiency syndrome therapeutic efficacies human recombinant alpha interferon IFN-alpha IFN-alpha zidovudine AZT AZT presymptomatic cats feline leukemia virus FeLV immunodeficiency syndrome FAIDS infection high levels persistent antigenemia Subcutaneous injection human recombinant IFN-alpha kg peak concentrations plasma U/ml postadministration half-life elimination dosage IFN-alpha cats weeks significant clinical toxicity Oral administration AZT mg/kg times peak concentrations plasma micrograms/ml half-life elimination Treatment FeLV-FAIDS-infected cats IFN-alpha combination AZT significant decreases core antigen weeks initiation therapy AZT effect virus antigen high U/kg low U/kg -dosage IFN-alpha cats refractory weeks beginning treatment times IFN-alpha-treated animals antibodies IFN-alpha specific human recombinant IFN-alpha dose dependent magnitude results study human recombinant IFN-alpha effective virus antigenic load cats FeLV-FAIDS 